Trial Profile

A Phase II Single-Arm Multicenter Study to Access Efficacy and Safety of P1101 in Chinese Polycythemia Vera Patients Who Are Intolerant or Resistance to Hydroxyurea

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ropeginterferon alfa-2b (Primary)
Indications Polycythaemia vera
Focus Therapeutic Use
Sponsors PharmaEssentia Corporation

Most Recent Events

01 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 May 2025.
30 Jun 2023 According to a PharmaEssentia Corporation media release, long-term treatment and follow-up of the patients in the study are planned to assess progression-free and overall survival.
30 Jun 2023 According to a PharmaEssentia Corporation media release, results published in Experimental Hematology & Oncology and co-authored by PharmaEssentia researchers.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com